Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting
July 23 2019 - 8:00AM
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces that
clinical data for ILUVIEN® (fluocinolone acetonide intravitreal
implant) 0.19mg, will be featured in four papers “on demand” as
part of the 2019 American Society of Retina Specialists (ASRS)
Annual Meeting being held July 26-30, 2019 at the Hyatt Regency in
Chicago.
ILUVIEN Presentations at ASRS:
Title:
“Intermittent to Continuous Therapy for Diabetic Macular Edema
Leads to Reduction in Treatment Frequency and Reduced Retinal
Thickness Fluctuations”Author:
Seenu M. Hariprasad, M.D., University of
Chicago Department of Ophthalmology
Title:
“Retinal Thickness Control Over Time, An Analysis of Standard
Deviation of CST in Patients with Diabetic Macular Edema Treated
with 0.19mg Fluocinolone Acetonide (FAc,
ILUVIEN)”Author:
Christopher D. Riemann, M.D., Cincinnati Eye Institute
Title:
“Interim 12-Month Anatomical, Safety and Visual Acuity Results From
Paladin in Diabetic Macular Edema Patients Receiving 0.19mg
Fluocinolone Acetonide (FAc, ILUVIEN) – Analysis of the Prior
Dexamethasone Cohort”Author:
Daniel Kiernan, M.D., PALADIN Investigators
Title:
“First Real-World Analysis of Safety in 0.19 Mg Fluocinolone
Acetonide (Fac, ILUVIEN) Implant-Treated Eyes Receiving
Supplemental Ocular Steroid Injection for Diabetic Macular Edema
(DME)”Author:
Victor Gonzalez, M.D., Valley Retina Institute, McAllen,
Tex.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period, approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About ILUVIEN
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant, injected into the back of
the eye. With its CONTINUOUS MICRODOSINGTM technology, ILUVIEN is
designed to release submicrogram levels of fluocinolone acetonide,
a corticosteroid, for up to 36 months, to reduce the recurrence of
disease, enabling patients to maintain vision longer with fewer
injections. ILUVIEN is approved in the U.S., Canada, Kuwait,
Lebanon and the U.A.E to treat diabetic macular edema (DME) in
patients who have been previously treated with a course of
corticosteroids and did not have a clinically significant rise in
intraocular pressure. In 17 European countries, ILUVIEN is
indicated for the treatment of vision impairment associated with
chronic DME considered insufficiently responsive to available
therapies. In March 2019, ILUVIEN received approval in the 17
countries under the Mutual Recognition Procedure for prevention of
relapse in recurrent non-infectious uveitis affecting the posterior
segment of the eye. The 17 European countries include the U.K.,
Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium,
Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the
Netherlands, and Luxembourg. The regulatory process is now in the
national phase in which the European member states have finalized
or are expected to finalize the label for the new indication to
meet each country’s local requirements. Timeline to this goal
varies by each country. ILUVIEN is not approved for treatment of
uveitis in the United States.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that
specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals for the management of
retinal diseases. Alimera is presently focused on diseases
affecting the back of the eye, or retina, because these diseases
are not well treated with current therapies and will affect
millions of people in our aging populations. For more information,
please visit www.alimerasciences.com.
For press inquiries: |
For investor inquiries: |
Jules Abraham |
Scott Gordon |
for Alimera Sciences |
for Alimera Sciences |
917-885-7378 |
scottg@coreir.com |
julesa@coreir.com |
|
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Sep 2023 to Sep 2024